Development of a pre-clinical dosimetry service with multipurpose small animal phantom for radiotherapy studies
Lead Participant:
NPL MANAGEMENT LIMITED
Abstract
The implementation of standardized and traceable dosimetry procedures for preclinical radiation studies
supported by an innovative multipurpose small animal phantom funded by Innovate UK to the tune of
£450,000 aims to significantly improve the quality and impact of radiobiological studies whilst reducing the
number of animals sacrificed. The collaboration includes the National Physical Laboratory, the UoH and Xstrahl
who will combine and utilise their extensive knowledge, expertise and facilities. The funding will enable the
partners to develop standards, equipment and techniques that will allow accurate monitoring of radiation
dosages to animals during preclinical trials, something which is not available at present, with the potential of
reducing the number of animals up to 50% for selected studies. The project will also enable scientists to
develop a better understanding of animal and human responses to radiation. The new phantom will provide
products and services to pharmaceutical companies interested in the development of drugs to aid radiation
treatments, and scientists across the globe to undertake novel and more accurate radiobiology research.
supported by an innovative multipurpose small animal phantom funded by Innovate UK to the tune of
£450,000 aims to significantly improve the quality and impact of radiobiological studies whilst reducing the
number of animals sacrificed. The collaboration includes the National Physical Laboratory, the UoH and Xstrahl
who will combine and utilise their extensive knowledge, expertise and facilities. The funding will enable the
partners to develop standards, equipment and techniques that will allow accurate monitoring of radiation
dosages to animals during preclinical trials, something which is not available at present, with the potential of
reducing the number of animals up to 50% for selected studies. The project will also enable scientists to
develop a better understanding of animal and human responses to radiation. The new phantom will provide
products and services to pharmaceutical companies interested in the development of drugs to aid radiation
treatments, and scientists across the globe to undertake novel and more accurate radiobiology research.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
  | ||
Participant |
||
NPL MANAGEMENT LIMITED |
People |
ORCID iD |
Giuseppe Schettino (Project Manager) |